Sutro Biopharma (STRO) Competitors $0.76 +0.08 (+12.35%) Closing price 07/2/2025 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.83%) As of 07/2/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock STRO vs. TRDA, ALLO, TSVT, ADCT, ANNX, AMRN, INZY, SGMT, RNAC, and CRVSShould you be buying Sutro Biopharma stock or one of its competitors? The main competitors of Sutro Biopharma include Entrada Therapeutics (TRDA), Allogene Therapeutics (ALLO), 2seventy bio (TSVT), ADC Therapeutics (ADCT), Annexon (ANNX), Amarin (AMRN), Inozyme Pharma (INZY), Sagimet Biosciences (SGMT), Cartesian Therapeutics (RNAC), and Corvus Pharmaceuticals (CRVS). These companies are all part of the "pharmaceutical products" industry. Sutro Biopharma vs. Its Competitors Entrada Therapeutics Allogene Therapeutics 2seventy bio ADC Therapeutics Annexon Amarin Inozyme Pharma Sagimet Biosciences Cartesian Therapeutics Corvus Pharmaceuticals Entrada Therapeutics (NASDAQ:TRDA) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Do analysts rate TRDA or STRO? Entrada Therapeutics presently has a consensus price target of $25.67, suggesting a potential upside of 253.05%. Sutro Biopharma has a consensus price target of $6.11, suggesting a potential upside of 700.30%. Given Sutro Biopharma's higher possible upside, analysts plainly believe Sutro Biopharma is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Sutro Biopharma 1 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.25 Is TRDA or STRO more profitable? Entrada Therapeutics has a net margin of 14.39% compared to Sutro Biopharma's net margin of -373.66%. Entrada Therapeutics' return on equity of 5.84% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Entrada Therapeutics14.39% 5.84% 4.61% Sutro Biopharma -373.66%-347.60%-59.46% Which has more volatility and risk, TRDA or STRO? Entrada Therapeutics has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.64, suggesting that its stock price is 64% more volatile than the S&P 500. Do insiders & institutionals have more ownership in TRDA or STRO? 86.4% of Entrada Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 8.1% of Entrada Therapeutics shares are held by company insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation & earnings, TRDA or STRO? Entrada Therapeutics has higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEntrada Therapeutics$210.78M1.31$65.63M$0.818.98Sutro Biopharma$62.04M1.04-$227.46M-$2.98-0.26 Does the media refer more to TRDA or STRO? In the previous week, Entrada Therapeutics had 15 more articles in the media than Sutro Biopharma. MarketBeat recorded 15 mentions for Entrada Therapeutics and 0 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.89 beat Entrada Therapeutics' score of 0.24 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Entrada Therapeutics Neutral Sutro Biopharma Very Positive SummaryEntrada Therapeutics beats Sutro Biopharma on 12 of the 16 factors compared between the two stocks. Get Sutro Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for STRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRO vs. The Competition Export to ExcelMetricSutro BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.43M$2.88B$5.54B$8.87BDividend YieldN/A2.64%5.39%4.10%P/E Ratio-0.2621.3126.1719.90Price / Sales1.04278.47413.55113.66Price / CashN/A41.4736.1356.90Price / Book1.417.518.025.38Net Income-$227.46M-$55.05M$3.15B$248.50M7 Day Performance-4.38%2.07%1.48%2.06%1 Month Performance-16.35%4.84%3.66%4.86%1 Year Performance-73.47%5.37%34.68%20.24% Sutro Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STROSutro Biopharma3.8614 of 5 stars$0.76+12.4%$6.11+700.3%-74.2%$57.43M$62.04M-0.26240Positive NewsTRDAEntrada Therapeutics3.367 of 5 stars$7.04-1.1%$25.67+264.6%-48.1%$267.17M$210.78M8.69110Trending NewsInsider TradeALLOAllogene Therapeutics3.4239 of 5 stars$1.22-0.8%$8.44+592.2%-44.4%$266.85M$20K-0.99310Gap DownTSVT2seventy bioN/A$5.00flat$5.00N/A$266.15M$48.37M-2.69440ADCTADC Therapeutics1.6753 of 5 stars$2.68-3.2%$7.75+189.2%-19.0%$265.80M$70.84M-1.85310ANNXAnnexon2.2374 of 5 stars$2.38flat$12.50+425.2%-38.4%$261.12MN/A-2.0260News CoveragePositive NewsAMRNAmarin0.7503 of 5 stars$12.60+0.5%$7.00-44.4%+18.1%$260.95M$228.61M-3.46360INZYInozyme Pharma3.4168 of 5 stars$3.99flat$11.75+194.5%N/A$257.60MN/A-2.3650News CoverageSGMTSagimet Biosciences2.5497 of 5 stars$8.36-4.1%$23.17+177.1%+176.8%$256.44M$2M-4.758RNACCartesian Therapeutics1.9745 of 5 stars$9.83+0.7%$43.00+337.4%-27.9%$255.09M$38.91M-0.1964Positive NewsCRVSCorvus Pharmaceuticals2.5508 of 5 stars$3.73-5.8%$15.00+302.1%+123.6%$254.27MN/A-3.8130Insider Trade Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Allogene Therapeutics Alternatives 2seventy bio Alternatives ADC Therapeutics Alternatives Annexon Alternatives Amarin Alternatives Inozyme Pharma Alternatives Sagimet Biosciences Alternatives Cartesian Therapeutics Alternatives Corvus Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRO) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersHere's the last trade you should make before heading out for the weekend tomorrow.Make this one trade at 2:59 PM on Friday afternoon, and you'll thank me on Monday morning.Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sutro Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sutro Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
